Published in J Neurosurg on July 01, 2007
Treatment of dystonia with deep brain stimulation. Neurotherapeutics (2008) 1.50
Effects of deep brain stimulation of the subthalamic nucleus on inhibitory and executive control over prepotent responses in Parkinson's disease. Front Syst Neurosci (2013) 1.22
Dystonia rating scales: critique and recommendations. Mov Disord (2013) 1.17
Short latency activation of cortex during clinically effective subthalamic deep brain stimulation for Parkinson's disease. Mov Disord (2012) 1.02
Induction of bradykinesia with pallidal deep brain stimulation in patients with cranial-cervical dystonia. Stereotact Funct Neurosurg (2009) 1.00
The subthalamic nucleus in primary dystonia: single-unit discharge characteristics. J Neurophysiol (2009) 1.00
Deep Brain Stimulation for Movement Disorders of Basal Ganglia Origin: Restoring Function or Functionality? Neurotherapeutics (2016) 0.96
Deep brain stimulation for movement disorders. Neurotherapeutics (2014) 0.89
Deep-Brain Stimulation for Basal Ganglia Disorders. Basal Ganglia (2011) 0.89
Levodopa-induced dyskinesias and their management. J Neurol (2008) 0.89
Deep brain stimulation for movement disorders. Considerations on 276 consecutive patients. J Neural Transm (Vienna) (2011) 0.82
Shorter pulse generator longevity and more frequent stimulator adjustments with pallidal DBS for dystonia versus other movement disorders. Brain Stimul (2014) 0.82
Current and future medical treatment in primary dystonia. Ther Adv Neurol Disord (2012) 0.79
Pallidal stimulation for primary generalised dystonia: effect on cognition, mood and quality of life. J Neurol (2013) 0.79
An evaluation of rating scales utilized for deep brain stimulation for dystonia. J Neurol (2009) 0.76
Deep brain stimulation for dystonia. Transl Neurodegener (2014) 0.76
Comparison of oscillatory activity in subthalamic nucleus in Parkinson's disease and dystonia. Neurobiol Dis (2016) 0.75
Effect of subthalamic nucleus deep brain stimulation on dual-task cognitive and motor performance in isolated dystonia. J Neurol Neurosurg Psychiatry (2014) 0.75
Study on Lesion Assessment of Cerebello-Thalamo-Cortical Network in Wilson's Disease with Diffusion Tensor Imaging. Neural Plast (2017) 0.75
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord (2008) 9.52
Frontotemporal dementia: clinicopathological correlations. Ann Neurol (2006) 5.14
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord (2007) 3.86
Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. Neurology (2012) 3.58
Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease. Am J Hum Genet (2003) 3.39
Biochemical and pathological characterization of Lrrk2. Ann Neurol (2006) 3.14
Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol (2006) 3.02
Facial emotion perception in schizophrenia: a meta-analytic review. Schizophr Bull (2009) 2.98
Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat Genet (2011) 2.97
Age at onset in two common neurodegenerative diseases is genetically controlled. Am J Hum Genet (2002) 2.90
The scientific and clinical basis for the treatment of Parkinson disease (2009). Neurology (2009) 2.62
An odor-specific threshold deficit implicates abnormal intracellular cyclic AMP signaling in schizophrenia. Am J Psychiatry (2008) 2.53
Subthalamic deep brain stimulation with a constant-current device in Parkinson's disease: an open-label randomised controlled trial. Lancet Neurol (2012) 2.50
Deep brain stimulation in the treatment of obesity. J Neurosurg (2008) 2.40
A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. JAMA Neurol (2013) 2.32
Conversion between mini-mental state examination, montreal cognitive assessment, and dementia rating scale-2 scores in Parkinson's disease. Mov Disord (2014) 2.30
Test characteristics of the 15-item geriatric depression scale and Hamilton depression rating scale in Parkinson disease. Am J Geriatr Psychiatry (2006) 2.26
Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease. Ann Neurol (2010) 2.20
Human substantia nigra neurons encode unexpected financial rewards. Science (2009) 2.16
Comparative accuracies of two common screening instruments for classification of Alzheimer's disease, mild cognitive impairment, and healthy aging. Alzheimers Dement (2012) 2.13
Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment. Acta Neuropathol (2010) 2.12
Neuropathologic substrates of Parkinson disease dementia. Ann Neurol (2012) 2.10
Parkin mutations and susceptibility alleles in late-onset Parkinson's disease. Ann Neurol (2003) 2.01
Effect of psychiatric and other nonmotor symptoms on disability in Parkinson's disease. J Am Geriatr Soc (2004) 2.00
Montreal cognitive assessment performance in patients with Parkinson's disease with "normal" global cognition according to mini-mental state examination score. J Am Geriatr Soc (2008) 1.92
Validation of the questionnaire for impulsive-compulsive disorders in Parkinson's disease. Mov Disord (2009) 1.89
Neuronal activity in the human subthalamic nucleus encodes decision conflict during action selection. J Neurosci (2012) 1.73
Recognition and treatment of depression in Parkinson's disease. J Geriatr Psychiatry Neurol (2003) 1.71
Impaired olfaction and other prodromal features in the Parkinson At-Risk Syndrome Study. Mov Disord (2012) 1.60
Distinct antemortem profiles in patients with pathologically defined frontotemporal dementia. Arch Neurol (2007) 1.60
Deep brain stimulation compared with methadone maintenance for the treatment of heroin dependence: a threshold and cost-effectiveness analysis. Addiction (2012) 1.58
Olfactory dysfunction is associated with neuropsychiatric manifestations in Parkinson's disease. Mov Disord (2011) 1.57
The Penn Conditional Exclusion Test: a new measure of executive-function with alternate forms of repeat administration. Arch Clin Neuropsychol (2004) 1.57
Deep brain stimulation for movement disorders: morbidity and mortality in 109 patients. J Neurosurg (2003) 1.49
Mild cognitive impairment is common in Parkinson's disease patients with normal Mini-Mental State Examination (MMSE) scores. Parkinsonism Relat Disord (2008) 1.49
Durability of Roux-en-Y gastric bypass surgery: a meta-regression study. Ann Surg (2012) 1.44
Functional near infrared spectroscopy (fNIRS): an emerging neuroimaging technology with important applications for the study of brain disorders. Clin Neuropsychol (2007) 1.38
Biomarker discovery for Alzheimer's disease, frontotemporal lobar degeneration, and Parkinson's disease. Acta Neuropathol (2010) 1.38
Oscillatory patterns in temporal lobe reveal context reinstatement during memory search. Proc Natl Acad Sci U S A (2011) 1.37
Neuropsychological decline in frontotemporal lobar degeneration: a longitudinal analysis. Neuropsychology (2009) 1.35
Evidence for impaired encoding and retrieval memory profiles in Parkinson disease. Cogn Behav Neurol (2004) 1.34
Antidepressant studies in Parkinson's disease: a review and meta-analysis. Mov Disord (2005) 1.32
Neuropsychological deficits among patients with late-onset minor and major depression. Arch Clin Neuropsychol (2003) 1.30
Pathological 43-kDa transactivation response DNA-binding protein in older adults with and without severe mental illness. Arch Neurol (2010) 1.29
Facial emotion perception in depression and bipolar disorder: a quantitative review. Psychiatry Res (2011) 1.27
Long-term follow-up of impulse control disorders in Parkinson's disease. Mov Disord (2008) 1.27
Neurodegeneration across stages of cognitive decline in Parkinson disease. Arch Neurol (2011) 1.26
Decreased ventral striatal activity with impulse control disorders in Parkinson's disease. Mov Disord (2010) 1.22
Olfactory epithelium amyloid-beta and paired helical filament-tau pathology in Alzheimer disease. Ann Neurol (2010) 1.20
Differential effects of deep brain stimulation target on motor subtypes in Parkinson's disease. Ann Neurol (2015) 1.20
Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease. Mov Disord (2009) 1.19
Potential outcome measures and trial design issues for multiple system atrophy. Mov Disord (2007) 1.18
Suicidal and death ideation in Parkinson's disease. Mov Disord (2008) 1.17
Psychiatric complications in Parkinson disease. Am J Geriatr Psychiatry (2005) 1.16
Dual-modality monitoring in a classification task: the effects of bilingualism and ageing. Q J Exp Psychol (Hove) (2006) 1.16
Striatal dopamine transporter imaging correlates with anxiety and depression symptoms in Parkinson's disease. J Nucl Med (2005) 1.15
Plasma apolipoprotein A1 as a biomarker for Parkinson disease. Ann Neurol (2013) 1.14
A recommended scale for cognitive screening in clinical trials of Parkinson's disease. Mov Disord (2010) 1.13
Symptoms versus neurocognitive test performance as predictors of psychosocial status in schizophrenia: a 1- and 4-year prospective study. Schizophr Bull (2005) 1.13
The preclinical detection of Parkinson's disease: ready for prime time? Ann Neurol (2004) 1.12
Effect of age on geriatric depression scale performance in Parkinson's disease. Mov Disord (2007) 1.12
Genetic influences on cognitive decline in Parkinson's disease. Mov Disord (2012) 1.10
Premotor Parkinson's disease: clinical features, detection, and prospects for treatment. Ann Neurol (2008) 1.10
Brain shift during deep brain stimulation surgery for Parkinson's disease. Stereotact Funct Neurosurg (2007) 1.10
Decrements in volume of anterior ventromedial temporal lobe and olfactory dysfunction in schizophrenia. Arch Gen Psychiatry (2003) 1.09
Scents and nonsense: olfactory dysfunction in schizophrenia. Schizophr Bull (2009) 1.08
Use of latent variable modeling to delineate psychiatric and cognitive profiles in Parkinson disease. Am J Geriatr Psychiatry (2009) 1.07
Memory-delineated subtypes of schizophrenia: relationship to clinical, neuroanatomical, and neurophysiological measures. Neuropsychology (2002) 1.04
Bilateral stimulation of the subthalamic nucleus in patients with Parkinson disease: a study of efficacy and safety. J Neurosurg (2002) 1.04
Low olfactory bulb volume in first-degree relatives of patients with schizophrenia. Am J Psychiatry (2003) 1.03
Physiologic impairment of olfactory stimulus processing in schizophrenia. Biol Psychiatry (2003) 1.03
Long-term outcomes of bilateral subthalamic nucleus stimulation in patients with advanced Parkinson's disease. Stereotact Funct Neurosurg (2006) 1.02
Falling in Parkinson disease: identifying and prioritizing risk factors in recurrent fallers. Am J Phys Med Rehabil (2007) 1.00
Category-specific neural oscillations predict recall organization during memory search. Cereb Cortex (2012) 0.99
Deep brain stimulation in the treatment of refractory epilepsy: update on current data and future directions. Neurobiol Dis (2009) 0.98